We are live on ! Find out more
AMED

Amedisys

Delisted

AMED was delisted on the 14th of August, 2025.

297 hedge funds and large institutions have $3.41B invested in Amedisys in 2018 Q4 according to their latest regulatory filings, with 64 funds opening new positions, 121 increasing their positions, 86 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

106% more first-time investments, than exits

New positions opened: 64 | Existing positions closed: 31

41% more repeat investments, than reductions

Existing positions increased: 121 | Existing positions reduced: 86

14% more call options, than puts

Call options by funds: $14.8M | Put options by funds: $13M

12% more funds holding

Funds holding: 265297 (+32)

2.68% less ownership

Funds ownership: 94.85%92.17% (-2.7%)

10% less capital invested

Capital invested by funds: $3.77B → $3.41B (-$361M)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
297
Holders Change
+32
Holders Change %
+12.08%
% of All Funds
6.62%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
64
Increased
121
Reduced
86
Closed
31
Calls
$14.8M
Puts
$13M
Net Calls
+$1.84M
Net Calls Change
+$6.92M
Name Holding Trade Value Shares
Change
Change in
Stake
WG
201
Winton Group
United Kingdom
$534K -$160K -1,356 -23%
FIM
202
Freedom Investment Management
Connecticut
$520K -$72.5K -615 -12%
PI
203
PEAK6 Investments
Illinois
$519K +$523K +4,434 New
Janus Henderson Group
204
Janus Henderson Group
United Kingdom
$509K -$46.6K -395 -8%
BNP Paribas Financial Markets
205
BNP Paribas Financial Markets
France
$503K +$264K +2,238 +109%
AB
206
Amalgamated Bank
New York
$493K +$276K +2,344 +126%
OAM
207
Origin Asset Management
United Kingdom
$469K -$58.9K -500 -11%
GHCM
208
Glen Harbor Capital Management
California
$469K
PA
209
Profund Advisors
Maryland
$460K -$191K -1,620 -29%
PNC Financial Services Group
210
PNC Financial Services Group
Pennsylvania
$459K +$38K +322 +9%
CANY
211
Caxton Associates (New York)
New York
$454K +$229K +1,945 +101%
PP
212
Paloma Partners
Connecticut
$436K -$2.57M -21,772 -85%
SDIC
213
South Dakota Investment Council
South Dakota
$433K
Commonwealth Equity Services
214
Commonwealth Equity Services
Massachusetts
$433K +$11.2K +95 +3%
NIT
215
NumerixS Investment Technologies
British Columbia, Canada
$428K +$23.6K +200 +6%
ProShare Advisors
216
ProShare Advisors
Maryland
$425K -$43.7K -371 -9%
PA
217
Perceptive Advisors
New York
$422K +$433K +3,672 New
Holocene Advisors
218
Holocene Advisors
New York
$420K +$422K +3,584 New
AL
219
AJO LP
Pennsylvania
$415K +$418K +3,543 New
Calamos Advisors
220
Calamos Advisors
Illinois
$410K +$413K +3,500 New
SSA
221
Schonfeld Strategic Advisors
New York
$403K +$405K +3,440 New
SAM
222
Sawgrass Asset Management
Florida
$399K +$402K +3,410 New
RCM
223
Riverhead Capital Management
Delaware
$381K
QI
224
Qtron Investments
Massachusetts
$373K +$376K +3,186 New
RJFSA
225
Raymond James Financial Services Advisors
Florida
$349K +$351K +2,978 New

AMED Hedge Fund Activity: Q4 2018 in Review

297 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Amedisys (AMED) for Q4 2018, worth a combined $3.41B — down 9.6% from $3.77B a quarter earlier.

Buyers outnumbered sellers: 64 funds opened new AMED positions and 31 closed out — a net gain of 33 holders — while 121 added to existing stakes and 86 trimmed.

The largest buyer was AllianceBernstein, adding an estimated $57.3M. The largest seller was Kohlberg Kravis Roberts & Co, cutting an estimated $272M.

  • 297 institutional investors held Amedisys (AMED) as of Q4 2018, up from 265 in Q3 2018.
  • Funds reported $3.41B of Amedisys stock for Q4 2018, down 9.6% quarter-over-quarter.
  • 64 funds opened new Amedisys positions in Q4 2018 and 31 closed out, a net change of +33 holders.
  • The largest Amedisys buyer in Q4 2018 was AllianceBernstein, an estimated $57.3M added.
  • The largest Amedisys seller in Q4 2018 was Kohlberg Kravis Roberts & Co, an estimated $272M sold.

Based on aggregated 13F filings for Q4 2018.